---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-26-000007"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:18:46.905643+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M

## Summary
- Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.
- Net loss for transition period $18.0M, improved from $30.6M; Adjusted EBITDA $13.1M, up from $2.6M.
- Gross margin 31% vs 26%; operating expenses decreased 31% to $24.4M.
- Signed five new programs during transition, including two commercial site transfer programs in Q4.
- Liquidity of $38.9M at quarter end; mid-term target: 12% revenue CAGR, EBITDA margins >25%.

## SEC filing metadata
- accession: 0001005286-26-000007
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/0001005286-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/lndc-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-26-000007
- JSON: https://secwatch.observer/filing/0001005286-26-000007.json
- Plain text: https://secwatch.observer/filing/0001005286-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.